Välbesökt på Hansa Medicals kapitalmarknadsdag
November 13, 2015 11:00 ET
|
Hansa Medical AB
Biopharmabolaget Hansa Medical AB (publ), som är noterat på Nasdaq Stockholms
huvudlista (ticker: HMED), höll idag, den 13 november 2015, kapitalmarknadsdag i
Ingenjörsvetenskapsakademiens lokaler i...
Well attended Capital Markets Day by Hansa Medical
November 13, 2015 11:00 ET
|
Hansa Medical AB
Biopharma Company Hansa Medical AB (publ), listed on Nasdaq Stockholm’s main
list (ticker: HMED), held today, November 13, 2015, a Capital Markets Day at
Royal Swedish Academy of Engineering Sciences...
Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies
November 13, 2015 02:45 ET
|
Hansa Medical AB
At Hansa Medical’s Capital Markets Day in Stockholm today, one of the world’s
leading transplantation experts, Professor Stanley Jordan at Cedars-Sinai
Medical Center, Los Angeles, will show data from...
Data visar att en dos av IdeS har gynnsam effekt och helt tar bort HLA-antikroppar
November 13, 2015 02:45 ET
|
Hansa Medical AB
Vid Hansa Medicals kapitalmarknadsdag i Stockholm idag kommer en av världens
ledande transplantationsexperter, professor Stanley Jordan vid Cedars-Sinai
Medical Center, Los Angeles, att visa data från...
Data som visar att IdeS kan inaktivera minnes-B-celler publicerade i Journal of Immunology
November 10, 2015 02:00 ET
|
Hansa Medical AB
Hansa Medical AB (publ) meddelar idag att resultat som beskriver IdeS effekt på
B-celler har publicerats i Journal of Immunology
Den vetenskapliga artikeln “The bacterial enzyme IdeS cleaves the...
Data showing that IdeS can silence memory B-cells published in Journal of Immunology
November 10, 2015 02:00 ET
|
Hansa Medical AB
Hansa Medical AB (publ) today announced that results on IdeS effect on B-cells
have been published in Journal of Immunology
The scientific article entitled “The bacterial enzyme IdeS cleaves the...
Hansa Medical interim report January – September 2015
October 28, 2015 03:00 ET
|
Hansa Medical AB
January – September 2015 in summary
Significant events during the third quarter
· Hansa Medical received FDA Orphan Drug Designation for IdeS in solid organ
transplant patients
· First patient...
Hansa Medical Delårsrapport januari- september 2015
October 28, 2015 03:00 ET
|
Hansa Medical AB
Januari – september 2015 i sammandrag
Väsentliga händelser under tredje kvartalet
· Amerikanska läkemedelsverket FDA godkänner Hansa Medicals ansökan om
särläkemedelsstatus (Orphan Drug...
Hansa Medical’s Nomination Committee appointed
October 27, 2015 03:30 ET
|
Hansa Medical AB
Hansa Medical AB’s Nomination Committee for the AGM 2016 will consist of Anders
Blom representing Nexttobe AB, Fredrik Bogren representing Farstorps Gård AB and
Astrid Samuelsson representing...
Hansa Medicals valberedning utsedd
October 27, 2015 03:30 ET
|
Hansa Medical AB
Hansa Medical AB:s valberedning inför årsstämman 2016 kommer att bestå av Anders
Blom som representant för Nexttobe AB, Fredrik Bogren som representant för
Farstorps Gård AB och Astrid Samuelsson som...